| Literature DB >> 28742856 |
Anna Yakovleva1, Jordan L Plieskatt1,2, Sarah Jensen1, Razan Humeida1,2, Jonathan Lang1,2, Guangzhao Li1, Paige Bracci3,4, Sylvia Silver1,2, Jeffrey Michael Bethony1,2.
Abstract
The demand for nucleic acid and protein derivatives from formalin-fixed paraffin-embedded (FFPE) tissue has greatly increased due to advances in extraction and purification methods, making these derivatives available for numerous genomic and proteomic platforms. Previously, DNA, RNA, microRNA (miRNA), or protein derived from FFPE tissue blocks were considered "unfit" for such platforms, as the process of tissue immobilization by FFPE resulted in cross-linked, fragmented, and chemically modified macromolecules. We conducted a systematic examination of nucleic acids and proteins co-extracted from 118 FFPE blocks sampled from the AIDS and Cancer Specimen Resource (ACSR) at The George Washington University after stratification by storage duration and the three most common tumor tissue types at the ACSR (adenocarcinoma, squamous cell carcinoma, and papillary carcinoma). DNA, RNA, miRNA, and protein could be co-extracted from 98% of the FFPE blocks sampled, with DNA and miRNA "fit" for diverse genomic purposes including sequencing. While RNA was the most labile of the FFPE derivatives, especially when assessed by RNA integrity number (RIN), it was still "fit" for genomic methods that use smaller sequence lengths, e.g., quantitative PCR. While more than half of the protein derivatives were fit for proteomic purposes, our analyses indicated a significant interaction effect on the absorbance values for proteins derived from FFPE, implying that storage duration may affect protein derivatives differently by tumor tissue type. The mean absorbance value for proteins derived from more recently stored FFPE was greater than protein derived from older FFPE, with the exception of adenocarcinoma tissue. Finally, the fitness of one type of derivative was weakly associated with the fitness of derivatives co-extracted from the same FFPE block. The current study used several novel quality assurance approaches and metrics to show that archival FFPE tissue blocks are a valuable resource for contemporary genomic and proteomic platforms.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28742856 PMCID: PMC5526578 DOI: 10.1371/journal.pone.0181756
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Fit for genomic and proteomic purposes by steps (numbered yellow boxes).
In step 1, the ACCESS database of the ACSR at GWU was used to construct a sampling frame of available FFPE blocks by cancer case, which were the sampling units used to avoid selecting multiple FFPE blocks from the same individual. In step 2, the sampling frame of FFPE blocks was stratified by intervals of 11 years of storage (1990–2001 and 2002–2013, inclusive) and then the three tumor tissue types with the highest frequency of FFPE in the ACSR at GWU. Simple random sampling without replacement was conducted in each stratum until the targeted sample size of 20 FFPE blocks per storage duration and tumor tissue type was reached. In step 3, commercial kits were employed to extract nucleic acids and protein from 10 μm FFPE sections from each block; a separate FFPE section was used for each type of nucleic acid or protein extraction. In step 4, an initial assessment for the presence of the nucleic acid or protein was conducted by ultraviolet absorbance (UV). In step 5, the purity and concentration of nucleic acid and protein extracts were determined by a SpectraDrop Micro-Volume Microplate with a SPECTRAmax 384PLUS plate reader and SoftMax Pro v6.4.1 software for device control and data analysis. In step 6, nucleic acid and protein derivatives were assigned to fitness categories as described in the Methods section. In step 7, the fitness of each FFPE block was assessed by ranking the combined fitness of the derivatives as follows: FFPE blocks that met the “Fit Nucleic Acids and Proteins for Diverse Analyses” requirements included blocks in which all four derivatives (DNA, RNA, miRNA, and protein) were “Fit”. FFPE blocks that were categorized as “Fit Nucleic Acids for Diverse Genomic Analyses” included blocks that were determined to have “Fit” nucleic acid derivatives only. FFPE blocks that had one or two "fit" or "above fit" derivative out of the three nucleic acid derivatives and “unfit”, "fit" or "above fit" protein derivatives, were considered “Fit for a Specific Genomic or Proteomic Analysis”. In step 8, if an FFPE block had no “Fit” molecular derivatives, it was considered a “Bad Block”.
Classification of FFPE block fitness as determined by the quality of nucleic acid and proteins derivatives.
| Fitness | Definition |
|---|---|
| Fit Nucleic Acids and Proteins for Diverse Analyses | Contains “fit” or “above fit” nucleic acids and protein derivatives in a concentration sufficient for downstream applications |
| Nucleic Acids Fit for Diverse Genomic Analyses | Contains a "fit" or "above fit" nucleic acid derivatives (e.g., DNA, RNA and miRNA) but "unfit" protein derivatives |
| Fit for a Specific Genomic or Proteomic Analysis | Only one or two "fit" or "above fit" derivative out of the three nucleic acid derivatives and “unfit”, "fit" or "above fit" protein derivatives |
| Bad Block (absent of any fit derivatives) | Contains nucleic acid or protein derivatives determined to be "unfit" |
Fig 2Box and whiskers plots showing the distribution of absorbance ratios (A260/280) for nucleic acids DNA, RNA, miRNA and for protein (A280) from FFPE.
Panel A shows derivatives from FFPE stored between 1990–2001 and Panel B derivative from FFPE stored between 2002–2013 stratified by storage duration (11 year intervals) and cancer tumor tissue type (adenocarcinoma, squamous cell, and papillary carcinoma).
Fig 3Box and whiskers plots showing the distribution of concentration (nanograms per microliter) for the nucleic acids DNA, RNA, and miRNA co-extracted from FFPE.
Panel A shows derivatives from FFPE stored between 1990–2001 and Panel B shows derivative from FFPE stored between 2002–2013.
The quality of DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue by the duration of storage (11 year intervals) and three tumor tissue types (n = 118).
| 1990–2001 | 2002–2013 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA 260/280 (Absorbance Ratio) | ||||||||||||
| Unfit | Fit | Above Fit | Unfit | Fit | Above Fit | |||||||
| Tissue Type | n | % | n | % | n | % | n | % | n | % | n | % |
| Papillary | 7 | 35 | 4 | 20 | 9 | 45 | 7 | 35 | 6 | 30 | 7 | 35 |
| Adenocarcinoma | 3 | 15 | 5 | 25 | 12 | 60 | 5 | 28 | 5 | 28 | 8 | 44 |
| Squamous | 6 | 30 | 5 | 25 | 9 | 45 | 7 | 35 | 4 | 20 | 9 | 45 |
| Total | 16 | 27 | 14 | 23 | 30 | 50 | 19 | 33 | 15 | 26 | 24 | 41 |
| DNA Concentration (Nanograms per microliter) | ||||||||||||
| < 5.00 | 5.00–50.00 | > 50.00 | < 5.00 | 5.00–50.00 | > 50.00 | |||||||
| Tissue Type | n | % | n | % | n | % | n | % | n | % | n | % |
| Papillary | 0 | 0 | 8 | 40 | 12 | 60 | 0 | 0 | 7 | 35 | 13 | 65 |
| Adenocarcinoma | 0 | 0 | 5 | 25 | 15 | 75 | 0 | 0 | 6 | 33 | 12 | 67 |
| Squamous | 1 | 5 | 8 | 40 | 11 | 55 | 1 | 5 | 6 | 30 | 13 | 65 |
| Total | 1 | 2 | 21 | 35 | 38 | 63 | 1 | 2 | 19 | 33 | 38 | 66 |
1 “Unfit” refers to DNA with a A260/280 ratio < 1.50 or > 2.50
2 “Fit” refers to DNA with an A260/280 ratio 1.50–1.80 (inclusive of the ratio values) or an A260/280 ratio between 2.20–2.50 (inclusive of the ratio values)
3 “Above Fit” refers to DNA with an A260/280 ratio between 1.80–2.20 (exclusive of the ratio values).
The quality of protein extracted from formalin-fixed paraffin-embedded (FFPE) tissue stratified by the storage duration (11 year intervals) and three tumor tissue types (n = 118).
| 1990–2001 | 2002–2013 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein (Absorbance at 280 nm) | |||||||||||||
| Unfit | Fit | Above Fit | Unfit | Fit | Above Fit | ||||||||
| Tissue Type | % | % | % | % | % | % | |||||||
| Papillary | 11 | 55 | 7 | 35 | 2 | 10 | 6 | 30 | 10 | 50 | 4 | 20 | |
| Adenocarcinoma | 3 | 15 | 14 | 70 | 3 | 15 | 7 | 39 | 9 | 50 | 2 | 11 | |
| Squamous | 14 | 70 | 6 | 30 | 0 | 0 | 10 | 50 | 7 | 35 | 3 | 15 | |
| Total | 28 | 47 | 27 | 45 | 5 | 8 | 23 | 40 | 26 | 45 | 9 | 16 | |
1 “Unfit” refers to protein with an A280 < 1.25
2 “Fit” refers to protein with an A280 1.25–2.50 (inclusive of these values)
3 “Above Fit” refers to protein with an A280 between > 2.50.
The quality of RNA extracted from FFPE by duration of storage and tumor tissue types (n = 118).
| 1990–2001 | 2002–2013 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNA 260/280 (Absorbance Ratio) | ||||||||||||
| Unfit | Fit | Above Fit | Unfit | Fit | Above Fit | |||||||
| Tissue Type | % | % | % | % | % | % | ||||||
| Papillary | 6 | 30 | 5 | 25 | 9 | 45 | 0 | 0 | 5 | 25 | 15 | 75 |
| Adenocarcinoma | 3 | 15 | 0 | 0 | 17 | 85 | 1 | 6 | 2 | 11 | 15 | 83 |
| Squamous | 3 | 15 | 5 | 25 | 12 | 60 | 3 | 15 | 3 | 15 | 14 | 70 |
| Total | 12 | 20 | 10 | 17 | 38 | 63 | 4 | 7 | 10 | 17 | 44 | 76 |
| RNA Concentration (Nanograms per microliter) | ||||||||||||
| < 5.00 | 5.00–50.00 | > 50.00 | < 5.00 | 5.00–50.00 | > 50.00 | |||||||
| Tissue Type | % | % | % | % | % | % | ||||||
| Papillary | 0 | 0 | 8 | 40 | 12 | 60 | 0 | 0 | 2 | 10 | 18 | 90 |
| Adenocarcinoma | 1 | 5 | 2 | 10 | 17 | 85 | 1 | 6 | 2 | 11 | 15 | 83 |
| Squamous | 0 | 0 | 3 | 15 | 17 | 85 | 0 | 0 | 3 | 15 | 17 | 85 |
| Total | 1 | 2 | 13 | 22 | 46 | 77 | 1 | 2 | 7 | 12 | 50 | 86 |
| RNA Integrity Number (RIN) | ||||||||||||
| Unfit | Fit | Above Fit | Unfit | Fit | Above Fit | |||||||
| Tissue Type | % | % | % | % | % | % | ||||||
| Papillary | 9 | 45 | 11 | 55 | 0 | 0 | 3 | 15 | 17 | 85 | 0 | 0 |
| Adenocarcinoma | 2 | 10 | 18 | 90 | 0 | 0 | 1 | 6 | 17 | 94 | 0 | 0 |
| Squamous | 6 | 30 | 13 | 65 | 1 | 5 | 4 | 20 | 16 | 80 | 0 | 0 |
| Total | 17 | 28 | 42 | 70 | 1 | 2 | 8 | 14 | 50 | 86 | 0 | 0 |
1 “Unfit” refers to RNA with a A260/280 ratio < 1.50 and > 2.50
2 “Fit” refers to RNA with an A260/280 ratio 1.50–1.80 (inclusive) or an A260/280 ratio between 2.20–2.50 (inclusive)
3 “Above Fit” refers to RNA with an A260/280 ratio between 1.80–2.20 (exclusive of the ratio values).
4 “Unfit” refers to RNA with a RIN < 2.00
5 “Fit” refers to RNA with a RIN within the range of 2.00–3.00 (inclusive of these RIN values); and
6 “Above fit” refers to RNA with a RIN > 3.00.
The quality of miRNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue by duration of storage (11 year intervals) and three tumor tissue types (n = 118).
| 1990–2001 | 2002–2013 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| miRNA 260/280 (Absorbance Ratio) | ||||||||||||
| Unfit | Fit | Above Fit | Unfit | Fit | Above | Fit | ||||||
| Tissue Type | n | % | n | % | n | % | n | % | n | % | n | % |
| Papillary | 3 | 15 | 4 | 20 | 13 | 65 | 0 | 0 | 4 | 20 | 16 | 80 |
| Adenocarcinoma | 2 | 10 | 1 | 5 | 17 | 85 | 1 | 6 | 1 | 6 | 16 | 89 |
| Squamous | 4 | 20 | 1 | 5 | 15 | 75 | 2 | 10 | 5 | 25 | 13 | 65 |
| Total | 9 | 15 | 6 | 10 | 45 | 75 | 3 | 5 | 10 | 17 | 45 | 78 |
| miRNA Concentration(Nanograms per microliter) | ||||||||||||
| Tissue Type | < 5.00 | 5.00–50.00 | > 50.00 | < 5.00 | 5.00–50.00 | > 50.00 | ||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Papillary | 1 | 5 | 5 | 25 | 14 | 70 | 0 | 0 | 1 | 5 | 19 | 95 |
| Adenocarcinoma | 1 | 5 | 1 | 5 | 18 | 90 | 1 | 6 | 0 | 0 | 17 | 94 |
| Squamous | 0 | 0 | 4 | 20 | 16 | 80 | 1 | 5 | 2 | 10 | 17 | 85 |
| Total | 2 | 3 | 10 | 17 | 48 | 80 | 2 | 3 | 3 | 5 | 53 | 91 |
1 “Unfit” refers to miRNA with a A260/280 ratio < 1.50 or > 2.50
2 “Fit” refers to miRNA with an A260/280 ratio 1.50–1.80 (inclusive) or an A260/280 ratio between 2.20–2.50 (inclusive)
3 “Above Fit” refers to miRNA with an A260/280 ratio between 1.80–2.20 (exclusive of the ratio values).
The fitness from formalin-fixed paraffin-embedded (FFPE) blocks tissue stratified by the storage duration (11 year intervals) and three tumor tissue types (n = 118) as categorized in Table 1.
| 1990–2001 | ||||||||
| Bad Block | Specific nucleic acid or protein | Nucleic Acids only | Fit for Diverse Analyses | |||||
| Tissue Type | % | % | % | % | ||||
| Papillary | 2 | 10 | 10 | 50 | 2 | 10 | 6 | 30 |
| Adenocarcinoma | 1 | 5 | 2 | 10 | 2 | 10 | 15 | 75 |
| Squamous | 3 | 15 | 6 | 30 | 8 | 40 | 3 | 15 |
| Total | 6 | 10 | 18 | 30 | 12 | 20 | 24 | 40 |
| 2002–2013 | ||||||||
| Bad Block | Specific nucleic acid or protein | Nucleic Acids only | Fit for Diverse Analyses | |||||
| Tissue Type | % | % | % | % | ||||
| Papillary | 0 | 0 | 8 | 40 | 2 | 10 | 10 | 50 |
| Adenocarcinoma | 1 | 6 | 4 | 22 | 4 | 22 | 9 | 50 |
| Squamous | 0 | 0 | 8 | 40 | 4 | 20 | 8 | 40 |
| Total | 1 | 2 | 20 | 34 | 10 | 17 | 27 | 47 |
Matrix of Spearman correlation coefficients between the numbers of failed derivatives in any set of two molecular extracts from the same block.
| Derivative | DNA | RNA | miRNA |
|---|---|---|---|
| RNA | 0.48 | ||
| miRNA | 0.52 | 0.58 | |
| Protein | 0.33 | 0.30 | 0.16 |
****p ≤ 0.0001
***p ≤ 0.001
*p ≤ 0.10